Contents

Glossary

• 1.8.1.2.1 Unscheduled Injectables
• 1.8.1.2.2 Fluorides
• 1.8.1.2.3 Sedating/Hypnotic Antihistamines (promethazine, doxylamine and diphenhydramine)
  • 1.8.1.2.3.1 Promethazine
  • 1.8.1.2.3.2 Meclozine
  • 1.8.1.2.3.3 Dimenhydrinate
• 1.8.1.2.4 Nitrofuran

Schedule 4 - Amendments

• 1.8.1.2.5 Nifursol
• 1.8.1.2.6 Nimorazole
• 1.8.1.3 Matters arising from NDPSC Consideration of TTHWP Items
  • 1.8.1.3.1 Hydroquinone
  • 1.8.1.3.2 Paracetamol
  • 1.8.1.3.3 Aspirin
  • 1.8.1.3.4 Pyridoxine
  • 1.8.1.3.5 Amphotericin
  • 1.8.1.3.6 Part 2 labels and containers
  • 1.8.1.3.7 Nicotine in NRT

Top of page

2. Proposed changes/additions to Parts 1 to 3 and Part 5 of the Standard for the Uniform Scheduling of Drugs and Poisons

• 2.3 SUSDP, Part 3
  • 2.3.1 Packaging of Schedule 8 Products
• 2.4 SUSDP, Part 5
  • 2.4.1 Appendix D - Paragraphs 2 and 6

Agricultural/Veterinary, Industrial and Domestic Chemicals

• 4.1 Labelling of Schedule 5 containers
• 4.2 Carbon Tetrachloride
• 4.3 Ivermectin

5. Proposed changes/additions to the Standard for the Uniform Scheduling of Drugs and Poisons

• 5.1 SUSDP, Part 4
  • 5.1.1 Creosote and related compounds and fractions
  • 5.1.2 methylcyclopentadienyl manganese tricarbonyl
  • 5.1.3 Virginiamycin

6. Matters referred by the Australian Pesticides and Veterinary Medicines Authority

• 6.1 1,2-Ethanediamine Polymer with (Chloromethyl) Oxirane and N-Methylmethanamine
• 6.2 Etoxazole
• 6.3 Endolsulfan
• 6.4 Deltamethrin
• 6.5 Ulocladium Oudemansii
• 6.6 Naphthalene

Top of page

7. Matters referred by Office of Chemical Safety (OCS) Branch

• 7.1 Home Garden Products - Pack sizes

8. Antibiotics for consideration following recommendations of the Joint Expert Technical Advisory Committee on Antibiotic Resistance (JETACAR)

• 8.1 Avilamycin
• 8.2 Bambermycin (Flavophospholipol)
• 8.3 Olaquindox
• 8.4 Cefadroxil
• 8.5 Penethamate Hydriodide
• 8.6 Phthalylsulfathiazole
• 8.7 Tylosin
• 8.8 Nalidixic Acid

Top of page

Pharmaceuticals

12. Matters arising from the minutes of the previous meeting (consideration of post-meeting submissions under 42ZCZ)

• 12.1 Levonorgestrel
• 12.2 Ibuprofen
• 12.3 Teriparatide
• 12.4 Fluconazole

13. Other outstanding matters from previous meetings

• 13.1 Silicones
• 13.2 Pseudoephedrine
• 13.4 Mitragynine
• 13.5 Trichloroacetic Acid
• 13.6 Memantine
• 13.7 Review of Non-Prescription Analgesics
  • 13.7.1 Paracetamol
  • 13.7.2 Aspirin
  • 13.7.3 Ibuprofen
  • 13.7.4 Naproxen
  • 13.7.5 Mefenamic acid
• 13.8 Ibuprofen
• 13.9 Hyoscyamus Niger

Top of page

14. Proposed changes/additions to the Standard for the Uniform Scheduling of Drugs and Poisons

• 14.1 SUSDP, Part 4
  • 14.1.1 Orlistat
  • 14.1.2 Paracetamol / Caffeine
  • 14.1.3 Fluticasone
  • 14.1.4 Kava (Piper Methysticum)
• 14.2 SUSDP, Part 5
  • 14.2.1 Appendix F - Consideration of Warning Statements for S2 Products
  • 14.2.2 Appendix G
    • 14.2.2.1 Mercury

15. Matters referred by the Australian Drug Evaluation Committee (ADEC)

• 15.1 New Substances
  • 15.1.1 Pimecrolimus
  • 15.1.2 Aripiprazole
  • 15.1.3 Anakinra
  • 15.1.4 Ezetimibe
  • 15.1.5 Gefitinib
  • 15.1.6 Fenofibrate
• 15.2 For Information (Substances Already Scheduled)
• 15.3 Other ADEC Matters for Consideration
  • 15.3.1 Pancreatic Enzyme Extract

Top of page

16. Other matters for consideration

• 16.1 Aminolevulinic Acid
• 16.2 Ibuprofen and Codeine
• 16.3 1,4-Butanediol, Gamma Aminobutyric Acid, Gamma Butyrolactone, Gamahydroxybutyraldehyde and Related Analogues

17. Matters referred by the Medicines Evaluation Committee (MEC)

• 17.1 Drometrizole Trisiloxane

18. Matters referred by the Medicines Classification Committee (MCC) of New Zealand

• 18.4 Sedating Antihistamines/Codeine

19. Initial review/formal opinions (pharmaceuticals)

• 22.1.1 3,4-methylenedioxy-N,a-dimethylphenylethylamine (MDMA)

24. Attachments

• Attachment 1 - Nicotine in NRT summary of post-meeting comments - Item 1.8.1.3.7
• Attachment 2 - Levonorgestrel summary of post-meeting comments - Item 12.1
• Attachment 3 - Ibuprofen summary of post-meeting comments - Item 12.2
• Attachment 4 - Summary and TGA response on the public comments received by the NDPSC following the June 2003 meeting (provided by MEC) - Item 13.7
  • General comments
  • Paracetamol
  • NSAIDS
    • 1. Aspirin
    • 2. Ibuprofen
    • 3. Naproxen
    • 4. Mefenamic Acid
    • Comments
• Attachment 5 - Summary of public submissions for Orlistat - Item 14.1.1